DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

Phase 2

Completed

Conditions: Breast Neoplasms
Breast Cancer

Interventions: Drug: Imiquimod

First Posted Date: 2009-05-12

Last Posted Date: 2015-12-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT00899574

Locations: 🇺🇸
NYU Cancer Institute, New York, New York, United States

Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00899821

Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia

Not Applicable

Terminated

Conditions: Spasmodic Dysphonia
Dystonia

Interventions: Behavioral: Vocal Exercise

First Posted Date: 2009-05-07

Last Posted Date: 2016-03-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00895063

Locations: 🇺🇸
Private Practice of Dr. Andrew Blitzer, New York, New York, United States

Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women

Completed

Conditions: Thrombophilia
Menopause

Interventions: Dietary Supplement: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]

First Posted Date: 2009-04-17

Last Posted Date: 2023-08-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 32

Registration Number: NCT00883272

Locations: 🇺🇸
251 East 33rd Street, New York, New York, United States

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Phase 1

Completed

Conditions: Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: Panobinostat
Drug: Bicalutamide

First Posted Date: 2009-04-09

Last Posted Date: 2018-02-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 52

Registration Number: NCT00878436

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
North Shore University Hospital-Monter Cancer Center, Lake Success, New York, United States

and more 1 locations

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: Docetaxel
Drug: Imatinib Mesylate

First Posted Date: 2009-03-13

Last Posted Date: 2016-06-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 24

Registration Number: NCT00861471

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Stomach Cancer

First Posted Date: 2009-03-09

Last Posted Date: 2016-03-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 28

Registration Number: NCT00858338

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Stomach Cancer

Interventions: Drug: Cetuximab
Drug: Irinotecan
Drug: Cisplatin
Procedure: Surgery
Drug: 5-FU
Radiation: Radiation

First Posted Date: 2009-03-06

Last Posted Date: 2015-12-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 30

Registration Number: NCT00857246

Locations: 🇺🇸
NYU Cancer Center, New York, New York, United States

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

Completed

Conditions: Postoperative Cognitive Dysfunction
Mild Cognitive Impairment

First Posted Date: 2009-02-25

Last Posted Date: 2016-03-17

Lead Sponsor: NYU Langone Health

Target Recruit Count: 41

Registration Number: NCT00850928

Locations: 🇺🇸
NYU School of Medicine, New York City, New York, United States

Cancer Screening and Prevention Program for High Risk Women

Completed

Conditions: Ovarian Cancer
Breast Cancer

First Posted Date: 2009-02-23

Last Posted Date: 2020-05-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 1452

Registration Number: NCT00849199

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy